Advertisement

Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S64–S67 | Cite as

Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa

  • M. J. Haverkorn
Article
  • 17 Downloads

Abstract

Thirty one patients were treated with oral ciprofloxacin for bronchitis withPseudomonas aeruginosa. Twenty eight patients had permanent and 14 transient risk factors. Nine patients had a hospital infection withPseudomonas aeruginosa. Sixteen patients were cured, complete or partial, butPseudomonas aeruginosa persisted or recurred in 19 patients. Patients with hospital infection did better than other patients. There was a significant decrease inin vitro susceptibility of persisting strains ofPseudomonas aeruginosa to ciprofloxacin and a tendency of recovery of susceptibility for the drug after treatment.

Key words

Bronchitis Ciprofloxacin Clinical evaluation Drug evaluation Hospital infection In vitro susceptibility 

References

  1. 1.
    Wise R, Andrews JM, Edwards LJ. In-vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother 1983;23:559–64.PubMedGoogle Scholar
  2. 2.
    Lennette EH, Balows A, Hauser WJ, Shadomy HJ. Manual of Clinical Microbiology 4th ed. Washington, D.C.: Am Soc Microbiol 1985.Google Scholar
  3. 3.
    Scully BE, Neu HC, Parry MF, Mandell W. Oral ciprofloxacin therapy of infections due toPseudomonas aeruginosa. Lancet 1986;1:819–22.PubMedGoogle Scholar
  4. 4.
    Follath F, Bindschedler M, Wenk M, Frei R, Stadler H, Reber H. Use of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:236–40.PubMedGoogle Scholar
  5. 5.
    Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment forPseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1:235–7.PubMedGoogle Scholar
  6. 6.
    Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixix acid. Antimicrob Agents Chemother 1984;25:633–7.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • M. J. Haverkorn
    • 1
  1. 1.Laboratory for Medical MicrobiologyRA EindhovenThe Netherlands

Personalised recommendations